Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Chief Medical Officer | July 14, 2026 | July 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-14 · Exercise / conversion · Acquired 16,250 · Balance 16,250 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Row 2 · 2026-07-14 · Sale · Disposed 16,250 · Balance 0 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16 | Direct | 48,750 |
Reported balance
After 2026-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-14 · Exercise / conversion · Disposed 16,250 · Balance 48,750 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026
F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 16,250 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2036-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 16,250 | $5.13 | $83,284.50 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 16,250 | $3.04 | $49,400.00 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 9 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,467 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F4 · derivative.exercise_date: The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 47,467 | $5.04 | $239,233.68 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 6 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F5 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 47,467 | $2.50 | $118,667.50 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 5 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 2,533 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 8 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 2,533 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F4 · derivative.exercise_date: The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 2,037 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 7 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 2,037 shares Expires 2034-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 2,533 | $5.00 | $12,665.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 2,533 | $2.50 | $6,332.50 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 2,037 | $5.00 | $10,185.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 2,037 | $2.20 | $4,481.40 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 7,557 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 7,557 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 7,557 | $3.14 | $23,728.98 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 7,557 | $1.23 | $9,295.11 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 568 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,057 Underlying: Common Stock · 568 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 568 | $3.10 | $1,761.03 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 568 | $1.23 | $698.64 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000038 · form4.xml · derivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000038 · form4.xml · derivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 21,446 | $3.65 | $78,204.98 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 25,499 | $3.90 | $99,407.85 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,446 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 13,055 | $4.20 | $54,789.22 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,945 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 21:53 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionRestricted Stock Unit · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · derivative · entry 5 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. F4 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. F4 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. F4 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,125 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000002 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 8,500 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 8,125 | $4.07 | $33,089.06 |
DisclosureSEC source: 0001133416-26-000002 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.15. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 8,125 | $1.23 | $9,993.75 |
DisclosureSEC source: 0001133416-26-000002 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · derivative · entry 7 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 8,500 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F4 · derivative.exercise_date: The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 6,463 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · derivative · entry 6 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,037 Underlying: Common Stock · 6,364 shares Expires 2034-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 8,500 | $7.04 | $59,840.00 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 5 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 8,500 | $2.50 | $21,250.00 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 6,463 | $7.04 | $45,499.52 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 6,463 | $2.20 | $14,218.60 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 4,479 | $7.04 | $31,532.16 |
DisclosureSEC source: 0001133416-25-000069 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 16,250 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · derivative · entry 10 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,750 Underlying: Common stock · 16,250 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F5 · derivative.exercise_date: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 41,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · derivative · entry 9 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 41,500 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F4 · derivative.exercise_date: The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 41,500 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · derivative · entry 8 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,500 Underlying: Common Stock · 41,500 shares Expires 2034-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 16,250 | $5.47 | $88,887.50 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 7 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,479 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 16,250 | $1.23 | $19,987.50 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 6 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 41,500 | $5.47 | $227,005.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 5 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,479 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 41,500 | $2.50 | $103,750.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 41,500 | $5.47 | $227,005.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,479 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 41,500 | $2.20 | $91,300.00 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 21,867 | $5.47 | $119,612.49 |
DisclosureSEC source: 0001133416-25-000054 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,479 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-25-000012 · form4.xml · derivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000012 · form4.xml · derivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-01-23 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000072 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.exercise_price: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. F3 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 13,654 | $0.88 | $12,044.19 |
DisclosureSEC source: 0001133416-24-000072 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,346 F2 · shares: Shares of common stock sold pursuant to previously disclosed 10b5-1 plan. F4 · price: Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8821. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 13:20 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-24-000072 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.